The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 633-643

  Wu, Chun Te ^a,b   Chen, Wen Cheng ^a   Liao, Shuen Kuei ^b   Hsu, Cheng Lung ^a,b   Lee, Kuan Der ^a,b   Chen, Miao Fen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL GROWTH; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE DOUBLE MINUTE 2 GENE; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION RESPONSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL AGING; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35948985191     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0073     Document Type: Article

References (38)

1. Achanta G & Huang P 2004 Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Research 64 6233-6239.
2. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW & Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of National Cancer Institute 91 1869-1876.
3. Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F & Tortora G 2004 Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clinical Cancer Research 10 4858-4864.
4. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ & Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57 205-225.
5. Brown JM & Attardi LD 2005 The role of apoptosis in cancer development and treatment response. Nature Reviews. Cancer 5 231-237.
6. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, de la Taille A, Kiss A & Buttyan R 2001 Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 48 225-230.
7. Cha TL, Qiu L, Chen CT, Wen Y & Hung MC 2005 Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Research 65 2287-2295.
8. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C & Mizokami A 1995 Androgen receptor: an overview. Critical Reviews in Eukaryotic Gene Expression 5 97-125.
9. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39.
10. Chen MF, Chen WC, Wu CT, Lin PY, Shau H, Liao SK, Yang CT & Lee KD 2006a p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment. International Journal of Radiation Oncology, Biology, Physics 66 1461-1472.
11. Chen MF, Lin CT, Chen WC, Yang CT, Chen CC, Liao SK, Liu JM, Lu CH & Lee KD 2006b The sensitivity of human mesenchymal stem cells to ionizing radiation. International Journal of Radiation Oncology, Biology, Physics 66 244-253.
12. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, Chopin D & Thiery JP 1995 Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 10 1269-1274.
13. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE & Sawyers CL 1999 Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Research 59 5030-5036.
14. Cronauer MV, Schulz WA, Burchardt T, Ackermann R & Burchardt M 2004 Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23 3541-3549.
15. Gaughan L, Logan IR, Neal DE & Robson CN 2005 Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Research 33 13-26.
16. Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. Journal of National Cancer Institute 93 1687-1697.
17. Hall EJ 2000 In Radiology for the Radiologist, p 347Ed EJ Hall., 5 Philadelphia: JB Lippincott.
18. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M & Miyamoto M 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Research 63 149-153.
19. Jones SN, Roe AE, Donehower LA & Bradley A 1995 Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 206-208.
20. Khor LY, Desilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H & Pollack A 2005 MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 104 962-967.
21. Lee AK 2006 Radiation therapy combined with hormone therapy for prostate cancer. Seminars in Radiation Oncology 16 20-28.
22. Levav-Cohen Y, Goldberg Z, Zuckerman V, Grossman T, Haupt S & Haupt Y 2005 C-Abl as a modulator of p53. Biochemical and Biophysical Research Communications 331 737-749.
23. Li M, Zhang Z, Hill DL, Chen X, Wang H & Zhang R 2005 Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Research 65 8200-8208.
24. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL & Chang C 2002 Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. Journal of Biological Chemistry 277 36570-36576.
25. Mu Z, Hachem P, Agrawal S & Pollack A 2004 Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. International Journal of Radiation Oncology, Biology, Physics 58 336-343.
26. Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC & Meistrich ML 2001 Lack of prostate cancer radiosensitization by androgen deprivation. International Journal of Radiation Oncology, Biology, Physics 51 1002-1007.
27. Polyak K, Xia Y, Zweier JL, Kinzler KW & Vogelstein B 1997 A model for p53-induced apoptosis. Nature 389 300-305.
28. Roach M III 1999 Current status of androgen suppression and radiotherapy for patients with prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 69 239-245.
29. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE & Chumakov PM 2005 The antioxidant function of the p53 tumor suppressor. Nature Medicine 11 1306-1313.
30. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B et al. 1997 Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. Journal of Urology 157 1731-1735.
31. Sengupta S & Wasylyk B 2001 Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes and Development 15 2367-2380.
32. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K & Shemshedini L 2001 p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. Journal of Biological Chemistry 276 38472-38479.
33. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG & Kung HJ 2002 Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research 62 6606-6614.
34. Tilley WD, Buchanan G, Hickey TE & Bentel JM 1996 Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research 2 277-285.
35. Tulard A, Hoffschir F, de Boisferon FH, Luccioni C & Bravard A 2003 Persistent oxidative stress after ionizing radiation is involved in inherited radiosensitivity. Free Radical Biology and Medicine 35 68-77.
36. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA & Mulder E 1992 Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31 2393-2399.
37. Wang H, Yu D, Agrawal S & Zhang R 2003 Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54 194-205.
38. Zegarra-Moro OL, Schmidt LJ, Huang H & Tindall DJ 2002 Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62 1008-1013.